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A 2-Step Approach to Myeloablative Haploidentical Stem Cell Transplantation with 
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We developed a 2-step approach to myeloablative haploidentical HSCT in which patients receive 
a large fixed dose of cyclophosphamide (CY)-tolerized T cells separately frm the HSC infusion 
in the hopes of accelerating post HSCT immune reconstitution (IR).  The uniformity of the T cell 
dosing facilitates comparison of patients without (low risk) and with (high risk) active 
malignancy at HSCT to ascertain the impact of disease status at HSCT on IR with fewer 
confounding effects from conditioning or T cell dosing.  
We analyzed IR at day +28 in patients receiving 2 step myeloablative haploidentical HSCT.  All 
patients received 12 Gy of total body irradiation followed by 2 x 10
8
 CD3+ cells/kg donor T cells 
(HSCT step 1).  CY 60 mg/kg/d x 2 was given starting 2 or 3 days after the T cell infusion in the 
low and high risk groups respectively. Tacrolimus and MMF were begun on day -1. A CD 34 
selected product was infused on day 0 (HSCT step 2) with median CD34 doses of 5.8 and 5.2 x 
10
6
/kg in the low and high-risk groups respectively.  
19 patients with AML (9), ALL (7), MDS (1), and NHL (2) without disease, and 16 patients with 
AML (10), ALL (2), MDS (3), and T cell NHL (1) with active disease at HSCT were analyzed. 
 A 17
th
 patient in the high risk group died prior to engraftment and was not fully evaluable. 
Outcomes for the low and high risk groups respectively with 2-24 months follow-up (median of 
9 in each group) were: no rejections; ANC >500: 11 versus 12 days; grades III-IV GVHD: 5.2% 
versus 18.7%; mortality from GVHD 0% versus 6.2%; infectious mortality: 0% versus 12.5%; 
non-infectious regimen-related mortality: 0% versus 11.7%; mortality from relapse; 5.2% versus 
18.7%; Overall survival: 94.8% versus 52.9%. By day +28, all patients had achieved CR and 
>95% donor marrow chimerism.  Compared to our experience with T cell depleted (TCD) 
HSCT, improved T and NK cell IR was observed, although the low risk group had higher median 
numbers of T cells.  Conversely, higher numbers of CD56
bright
 NK cells were present in the high 
risk group. 
Compared to TCD approaches at our institution and others, the 2 step approach allows for 
stronger early IR with low infectious mortality in patients without and with active malignancy at 
HSCT. IR was more robust in patients without active disease.  IR in the higher risk group may be 
hindered by less hospitable marrow stroma and a greater baseline inflammation related to the 
active malignancy and exacerbated by the HSCT. The increased rate of significant GVHD and 
the prominence of NK
bright
 cells, which are strong producers of cytokines, may reflect this higher 
state of inflammation. In addition, differences in the degree of T cell eradication by CY, based 
on T cell responses to malignancy or the longer period of T cell activation in the high risk 
regimen, may account for variations in IR between the groups. Recognition of the differences in 
early IR amongst specific patient populations may help optimize post HSCT care. 
 
